Home / News / BioBlast®



Explore our interactive biosimilar news updates, collating tailored reports by brand, INN, originator/biosimilar applicant, litigation, region, or date. Alternatively, review our weekly BioBlast™ updates below.
Scientific Name: eculizumab


Samsung Bioepis secured 10 biosimilar products on its 10th year anniversary

February 28, 2022

The Korea Herald reported that Samsung Bioepis has secured a total of 10 biosimilar products on its 10th year anniversary.  Six biosimilars have been approved globally: infliximab, etanercept, adalimumab, trastuzumab, bevacizumab and ranibizumab.  Eculizumab has recently completed its Ph III clinical trial, and three other biosimilar candidates are under Ph III trials.


Samsung Bioepis announces results from Ph I study of SB12 (proposed eculizumab biosimilar)

December 11, 2021

Samsung Bioepis announced that SB12 (proposed eculizumab biosimilar) met all the endpoints in a Ph I study.

Samsung Bioepis completes Ph III trials of SB12 (proposed eculizumab biosimilar) for the treatment of paroxysmal nocturnal hemoglobinuria

October 27, 2021

Korea Biomedical Review announced that Samsung Bioepis has completed Ph III trials of SB12 (proposed eculizumab biosimilar) for the treatment of paroxysmal nocturnal hemoglobinuria.


AstraZeneca to acquire Alexion

December 12, 2020

Biopharma supplier Alexion announces it will be acquired by AstraZeneca. The acquisition is expected to close in Q3 2021 for total consideration to Alexion shareholders of $39bn. Under the deal, AstraZeneca will acquire Alexion’s pipeline of 11 molecules, as well as Alexion’s blockbuster products Soliris® (eculizumab) and Ultomiris® (ravulizumab).

Alexion and Amgen announce eculizumab settlement

May 29, 2020

In a filing to the Securities and Exchange Commission, Alexion announces it has settled its eculizumab dispute with Amgen. Under the agreement, Amgen will receive a non-exclusive, royalty-free license to market its product from 01 March 2025.

CN | Samsung and AffaMed announce approval for Ph III eculizumab trials

January 10, 2020

Samsung and AffaMed announce Chinese approval for Phase III trials of eculizumab candidate.


EU | Alexion reveals EPO denied two eculizumab patent applications

September 9, 2019

Alexion reveals that the EPO denied two patent applications relating to its eculizumab product, as they await the full written response.

US | US PTAB commences inter partes review of eculizumab patents

September 2, 2019

US Patent and Trial Board commences an inter partes review of Alexion’s eculizumab patents following Amgen’s claims that they were anticipated or obvious.

Samsung Bioepis commences Ph III eculizumab trials

August 16, 2019

Samsung Bioepis commences patient enrolment for Phase III clinical study of eculizumab biosimilar candidate, SB12.

RU | Selexis announces first biosimilar eculizumab approval in Russia

April 11, 2019

Selexis announces first biosimilar eculizumab approval in Russia through partnership with Generium. 

Samsung Bioepis enters commercialisation partnership with C-Bridge

February 26, 2019

Samsung Bioepis partners with C-Bridge to commercialise biosimilars in China. Under the deal, C-Bridge will develop a new company, AffaMed Therapeutics to launch candidates such as ranibizumab, eculizumab and trastuzumab biosimilars.

BioBlast® extract From February 26, 2019 to February 28, 2022